Treatment of Genotype 1 HCV Treatment-Naïve Patients: final results of phase III study ADVANCE
T Berg, P Buggisch, P Malinski, H Diepolder, S Mauss, J Rasenack, T Goeser, WE Schmidt, R Kauffman, M Beumont-Mauviel, S Decker-Burgard, S Zeuzem · Zeitschrift für Gastroenterologie · 2011 · Heft 01
Bibliografische Angaben
Zusammenfassung
ADVANCE study is a 3-arm double-blind, randomized, placebo-controlled Phase 3 study assessing efficacy and safety of two telaprevir (T)-based response-guided regimens compared with peginterferon alfa-2a 180µg/week and ribavirin 1000–1200mg/day (PR) in treatment-naïve patients (pts) with chronic genotype 1 HCV infection. Methods: Treatment arms wereT 750mg q8h in combination with PR for 8 weeks, followed by additional weeks of PR; T 750mg q8h in combination with PR for 12 weeks, followed by additional weeks of PR; PR for 48 weeks. Pts in T arms achieving an extended rapid viral response (eRVR) received a total of…
